TX
Texas House Bill HB2030

Texas 2009 - 81st Regular

Texas House Bill HB2030

Filed
 
Out of House Committee
3/30/09  
Voted on by House
4/8/09  
Out of Senate Committee
5/8/09  
Voted on by Senate
5/12/09  
Governor Action
6/19/09  
Bill Becomes Law
 
Enrolled
6/1/09  

Caption

Relating to the Medicaid Drug Utilization Review Program and prescription drug use under the Medicaid program.

Impact

Implementing HB2030 is expected to improve pharmaceutical care under the Medicaid program by addressing ongoing drug therapy problems through detailed reviews. The law will require the Medicaid program to monitor both drug usage and expenditures, thereby enabling the identification of high-cost drugs and therapeutic classes. By doing so, it aims to provide insights into prescription practices, potentially leading to lower costs and better healthcare outcomes for Medicaid recipients.

Summary

House Bill 2030 aims to enhance the effectiveness of the Medicaid Drug Utilization Review Program by mandating the Texas Medicaid program to perform more extensive and diverse drug use reviews. This includes increasing the number and types of retrospective drug use reviews each year, which are designed to identify patterns in prescribing and improve overall drug therapy quality. The bill outlines specific requirements for the commission overseeing these reviews, focusing on cost-saving evaluations and the sharing of data through annual reports posted online.

Contention

During discussions surrounding HB2030, key points of contention revolved around concerns related to conflicts of interest. The bill specifically prohibits board members of the Medicaid Drug Utilization Review Program from having financial relationships with pharmaceutical manufacturers. This provision aims to ensure impartiality in the review process, yet some stakeholders raised questions regarding enforcement and the sufficiency of these measures to fully mitigate potential biases. As the bill advances, the implications for board operations and potential pushback from pharmaceutical interests could become focal points of debate.

Companion Bills

TX SB946

Identical Relating to the Medicaid Drug Utilization Review Program and prescription drug use under the Medicaid program.

Previously Filed As

TX HB3286

Relating to prescription drug benefits under Medicaid and the child health plan program.

TX HB1293

Relating to the reimbursement of prescription drugs under Medicaid and the child health plan program.

TX SB2201

Relating to certain prescription drug benefits under the Medicaid managed care program.

TX HB1283

Relating to prescription drug formularies applicable to the Medicaid managed care program.

TX SB1113

Relating to prescription drug formularies applicable to the Medicaid managed care program.

TX HB3214

Relating to the determination of prescription drug reimbursement amounts under the Medicaid vendor drug program.

TX SB1619

Relating to the determination of prescription drug reimbursement amounts under the Medicaid vendor drug program.

TX HB3026

Relating to the administration of a prescription drug manufacturer or third-party prescription assistance program.

TX SB2173

Relating to a pilot program for the safe disposal of prescription drugs, including controlled substance prescription drugs.

TX HB1373

Relating to a pilot program for the safe disposal of controlled substance prescription drugs.

Similar Bills

LA SB239

Provides relative to the Medicaid prescription drug benefit program. (8/1/19) (EN SEE FISC NOTE GF EX See Note)

CT SB00068

An Act Concerning The Department Of Social Services' Recommended Changes To The Medical Assistance And Pharmacy Statutes.

IN SB0140

Pharmacy benefits.

FL H0183

Medicaid Step-therapy Protocols for Drugs for Serious Mental Illness Treatments

LA SB29

Provides relative to a single uniform prescription drug prior authorization form. (See Act) (RE SEE FISC NOTE SG EX See Note)

KY HJR28

A JOINT RESOLUTION directing the Department for Medicaid Services to request guidance from the Centers for Medicare and Medicaid Services for Medicaid coverage on prescription digital therapeutics in the Commonwealth of Kentucky.

CT HB06545

An Act Concerning Medicaid Drug Step Therapy.

WV SB511

Prohibiting insurers deny prescription drugs for addiction treatment in certain circumstances